Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients Data in more than 30 abstracts
Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society.
Amgen Announces New Data Being Presented At ASH 2021 morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.